• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溃疡性结肠炎和克罗恩病的病因及发病机制的当前概念

Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

作者信息

Sartor R B

机构信息

University of North Carolina at Chapel Hill, USA.

出版信息

Gastroenterol Clin North Am. 1995 Sep;24(3):475-507.

PMID:8809232
Abstract

Although the causes, events initiating and triggering inflammation, and the precise immunoregulatory defects of IBD are still not known, investigations have provided a better understanding of the mechanisms of perpetuation of inflammation, genetic susceptibility, tissue injury, and symptoms. Ulcerative colitis and Crohn's disease are related disorders that probably share susceptibility genes and have similar nonspecific inflammatory mediator profiles. These diseases, however, almost certainly have different causes and respond to different antigenic stimuli. It is probable that both ulcerative colitis and Crohn's disease represent heterogenic groups of diseases that share similar mechanisms of tissue damage but have different initiating events and immunoregulatory abnormalities. Rodent models demonstrate that a wide variety of initial injuries or perturbations of immunoregulatory pathways can lead to similar phenotypes of intestinal injury, and human studies show evidence of genetic heterogeneity. It is equally apparent from these models that initiating and perpetuating mechanisms are entirely distinct and that the intestine has a remarkable ability to heal. Chronicity of disease depends on continued exposure to toxic luminal components, most commonly of bacterial origin, and genetically determined host susceptibility. Precise mechanisms of differential genetic susceptibility remain unclear, but defective down-regulation of inflammation is consistent with clinical and experimental observations. The author proposes the following sequence of events (Fig. 9). Nonspecific intestinal inflammation can be induced by a wide variety of enteric infections or ingested toxins. Resultant increased mucosal permeability leads to enhanced uptake of toxic luminal bacterial products, which potentiate local injury. The vast majority of hosts respond to these injurious events by promptly down-regulating the inflammatory response and rapidly healing the mucosal damage without residual scarring. The genetically susceptible host, however, who lacks the ability to suppress the inflammatory response efficiently, has inappropriate amplification of the immune cascade. In response to constant exposure to phlogistic luminal constituents, these patients develop an unrestrained inflammatory response, leading to tissue destruction, chronic inflammation, and fibrosis. Thus, IBD is caused by a genetically determined defective down-regulation of inflammation driven by ubiquitous antigens. Luminal anaerobic bacterial antigens are the stimuli in Crohn's disease, but ulcerative colitis may be caused by functionally abnormal aerobic bacteria or primary defects in epithelial cell physiology. Spontaneous or therapy-induced remissions can be achieved, but the risk of reactivation of inflammation is high because of the frequent exposure to triggering episodes that can reignite the inflammatory cascade. [formula: see text] This theory suggests that the intestine is in a constant state of controlled inflammation, mediated by a balance between aggressive luminal forces and host protective mechanisms (Fig. 10). This delicate balance can be deranged by any number of environmental triggering events and is in dysequilibrium in IBD. Amplification of the inflammatory response activates effector cells and cascades of soluble inflammatory molecules, which mediate tissue injury and physiologic responses leading to symptoms of IBD. These relatively nonspecific events are the target of most current therapeutic agents, which can inhibit but not completely block intestinal inflammation because of the overwhelming number of parallel pathways involved. Specific inhibition of selected effector molecules is intellectually intriguing but is less likely to paralyze the inflammatory response during clinically apparent inflammation than is blockade of key immunoregulatory cells and molecules. Better understanding of initiating, perpetuating, and immunoregulatory mechanisms should provide more

摘要

尽管炎症性肠病(IBD)的病因、引发和触发炎症的事件以及确切的免疫调节缺陷仍不明确,但研究已使我们对炎症持续存在、遗传易感性、组织损伤和症状的机制有了更好的理解。溃疡性结肠炎和克罗恩病是相关疾病,可能共享易感基因且具有相似的非特异性炎症介质谱。然而,这些疾病几乎肯定有不同的病因,并对不同的抗原刺激产生反应。溃疡性结肠炎和克罗恩病很可能都代表异质性疾病组,它们具有相似的组织损伤机制,但起始事件和免疫调节异常不同。啮齿动物模型表明,多种初始损伤或免疫调节途径的扰动可导致相似的肠道损伤表型,而人体研究也显示出遗传异质性的证据。从这些模型中同样明显的是,起始机制和持续机制完全不同,而且肠道具有显著的愈合能力。疾病的慢性化取决于持续接触有毒的肠腔成分,最常见的是细菌来源的成分,以及遗传决定的宿主易感性。不同遗传易感性的确切机制仍不清楚,但炎症下调缺陷与临床和实验观察结果一致。作者提出了以下事件序列(图9)。多种肠道感染或摄入的毒素可诱发非特异性肠道炎症。由此导致的黏膜通透性增加会增强对有毒肠腔细菌产物的摄取,从而加剧局部损伤。绝大多数宿主通过迅速下调炎症反应并快速愈合黏膜损伤且不留残余瘢痕来应对这些损伤事件。然而,缺乏有效抑制炎症反应能力的遗传易感宿主会出现免疫级联反应的不适当放大。由于持续接触炎性肠腔成分,这些患者会产生不受控制的炎症反应,导致组织破坏、慢性炎症和纤维化。因此,IBD是由普遍存在的抗原驱动的、遗传决定的炎症下调缺陷所致。肠腔厌氧细菌抗原是克罗恩病的刺激因素,但溃疡性结肠炎可能由功能异常的需氧菌或上皮细胞生理学的原发性缺陷引起。可以实现自发缓解或治疗诱导的缓解,但由于频繁接触可重新引发炎症级联反应的触发事件,炎症复发的风险很高。[公式:见正文] 该理论表明,肠道处于由侵袭性肠腔力量与宿主保护机制之间的平衡介导的持续受控炎症状态(图10)。这种微妙的平衡可能因任何数量的环境触发事件而失调,在IBD中处于失衡状态。炎症反应的放大激活效应细胞和可溶性炎症分子级联反应,介导组织损伤和导致IBD症状的生理反应。这些相对非特异性的事件是大多数当前治疗药物的靶点,由于涉及大量平行途径,这些药物可以抑制但不能完全阻断肠道炎症。对选定效应分子的特异性抑制在理论上很有吸引力,但在临床明显炎症期间,与阻断关键免疫调节细胞和分子相比,不太可能使炎症反应瘫痪。对起始、持续和免疫调节机制的更好理解应能提供更多……

相似文献

1
Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病的病因及发病机制的当前概念
Gastroenterol Clin North Am. 1995 Sep;24(3):475-507.
2
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.疾病机制:克罗恩病和溃疡性结肠炎的发病机制
Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407. doi: 10.1038/ncpgasthep0528.
3
Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases.慢性炎症性肠病的发病机制与免疫机制
Am J Gastroenterol. 1997 Dec;92(12 Suppl):5S-11S.
4
Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications.克罗恩病中的细菌:炎症机制及治疗意义
J Clin Gastroenterol. 2007 May-Jun;41 Suppl 1:S37-43. doi: 10.1097/MCG.0b013e31802db364.
5
Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy.炎症性肠病。发病机制的当前概念及其对治疗的影响。
Minerva Gastroenterol Dietol. 2002 Sep;48(3):215-26.
6
A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.肠道黏膜上皮细胞在炎症性肠病发病机制中的免疫调节作用的原发性失调?作为克罗恩病与溃疡性结肠炎组织模式实体的炎症反应生物学。
J Theor Biol. 2004 Mar 21;227(2):219-28. doi: 10.1016/j.jtbi.2003.11.002.
7
[Pathogenetic models ulcerative colitis and Crohn disease].[溃疡性结肠炎和克罗恩病的发病机制模型]
Verh Dtsch Ges Pathol. 1996;80:104-8.
8
DNA-driven nutritional therapy of inflammatory bowel disease.炎症性肠病的DNA驱动营养疗法。
Nutrition. 2009 Sep;25(9):885-91. doi: 10.1016/j.nut.2009.06.011.
9
Etiology and pathogenesis of inflammatory bowel disease.炎症性肠病的病因及发病机制
Minerva Gastroenterol Dietol. 2005 Jun;51(2):127-45.
10
[Intestinal flora and Crohn's disease].[肠道菌群与克罗恩病]
Ann Pharm Fr. 2003 Jul;61(4):276-81.

引用本文的文献

1
Inflammatory Bowel Disease from the Perspective of Newer Innate Immune System Biomarkers.从新型固有免疫系统生物标志物角度看炎症性肠病
Gastrointest Disord (Basel). 2025 Mar 6;7(1):22. doi: 10.3390/gidisord7010022.
2
Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption.克罗恩病中肠道药物代谢酶和转运体的变异性及其对口服药物吸收的潜在影响。
Br J Clin Pharmacol. 2025 Jul;91(7):2028-2044. doi: 10.1002/bcp.70019. Epub 2025 Mar 4.
3
The Impact of the CB Cannabinoid Receptor in Inflammatory Diseases: An Update.
CB 大麻素受体在炎症性疾病中的作用:最新研究进展。
Molecules. 2024 Jul 18;29(14):3381. doi: 10.3390/molecules29143381.
4
Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel disease.基因共表达网络揭示了长链非编码 RNA 在炎症性肠病中的广泛作用。
JCI Insight. 2024 Feb 8;9(3):e168988. doi: 10.1172/jci.insight.168988.
5
Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.间充质干细胞(MSCs)为基础的细胞疗法治疗炎症性肠病(IBD)的治疗潜力。
Eur J Med Res. 2023 Jan 27;28(1):47. doi: 10.1186/s40001-023-01008-7.
6
The Evaluation of Transmural Healing by Low-dose Computed Tomography Enterography in Patients with Crohn's Disease.经低剂量计算机断层扫描小肠造影评估克罗恩病患者的透壁愈合情况。
Intern Med. 2022;61(20):2999-3007. doi: 10.2169/internalmedicine.9066-21. Epub 2022 Oct 15.
7
Network Pharmacology-Based Strategy to Identify the Pharmacological Mechanisms of Decoction against Crohn's Disease.基于网络药理学的策略识别芍药汤治疗克罗恩病的药理机制
Front Pharmacol. 2022 Apr 5;13:844685. doi: 10.3389/fphar.2022.844685. eCollection 2022.
8
Nanoparticles Carrying NF-κB p65-Specific siRNA Alleviate Colitis in Mice by Attenuating NF-κB-Related Protein Expression and Pro-Inflammatory Cellular Mediator Secretion.携带NF-κB p65特异性小干扰RNA的纳米颗粒通过减弱NF-κB相关蛋白表达和促炎细胞介质分泌减轻小鼠结肠炎。
Pharmaceutics. 2022 Feb 15;14(2):419. doi: 10.3390/pharmaceutics14020419.
9
Therapeutic efficacy of rifaximin loaded tamarind gum polysaccharide nanoparticles in TNBS induced IBD model Wistar rats.罗氟沙星负载罗望子胶多糖纳米颗粒在三硝基苯磺酸诱导的Wistar大鼠炎症性肠病模型中的治疗效果
Rep Pract Oncol Radiother. 2021 Sep 30;26(5):712-729. doi: 10.5603/RPOR.a2021.0100. eCollection 2021.
10
ABIN1 alleviates inflammatory responses and colitis facilitating A20 activity.ABIN1通过促进A20活性减轻炎症反应和结肠炎。
Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320944782. doi: 10.1177/2040622320944782. eCollection 2020.